A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Resistant/Refractory Multiple Myeloma

Trial Profile

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Resistant/Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Selinexor (Primary) ; Bortezomib; Daratumumab; Dexamethasone; Lenalidomide; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms STOMP
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 01 Nov 2017 According to a Karyopharm Therapeutics media release, updated data from this trial will be presented at the American Society of Hematology (ASH) 2017 annual meeting.
    • 08 Aug 2017 According to a Karyopharm Therapeutics media release, the company has dosed patients in a newly initiated SDd arm.The SDd arm of the STOMP study is expected to enroll up to 16 patients and the Company expects to report top-line data in the first half of 2018.
    • 08 Aug 2017 According to a Karyopharm Therapeutics media release, the company expects to report updated data on all oral regimens by year end 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top